MELA Sciences, Inc. (MELA)
-NasdaqCM 1.06 
0.03(2.75%) 4:00PM EDT
| Prev Close: | 1.09 |
|---|
| Open: | 1.09 |
|---|
| Bid: | 1.05 x 16700 |
|---|
| Ask: | 1.06 x 4800 |
|---|
| 1y Target Est: | 3.25 |
|---|
| Beta: | -0.17 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.04 - 1.10 |
|---|
| 52wk Range: | 1.02 - 4.69 |
|---|
| Volume: | 547,483 |
|---|
| Avg Vol (3m): | 531,461 |
|---|
| Market Cap: | 45.62M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.74 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- MELA Sciences' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 1)
- MELA Sciences Announces First Quarter 2013 Financial ResultsGlobeNewswire(Tue, Apr 30)
- MELA SCIENCES, INC. /NY Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EEDGAR Online(Tue, Apr 30)
- Q1 2013 MELA Sciences Earnings Release - After Market CloseCCBN(Tue, Apr 30)
- MELA SCIENCES, INC. /NY Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Sun, Apr 28)
- 5 Stocks Under $10 Set to Soarat TheStreet(Thu, Apr 25)
- MELA Sciences, Inc. Partners With Dermatologists Nationwide To Promote Skin Cancer AwarenessPR Newswire(Tue, Apr 23)
- MELA Sciences to Host Investor Meeting in Conjunction With Melanoma Monday on May 6th 2013 in New YorkGlobeNewswire(Thu, Apr 18)
- MELA Sciences to Participate in Upcoming 12th Annual Needham Healthcare ConferenceGlobeNewswire(Mon, Apr 15)
- MELA Sciences to Release First Quarter 2013 Financial Results and Host Conference Call on Tuesday, April 30, 2013GlobeNewswire(Wed, Apr 10)
- When Will Mela Science's Price Become Sustainable?at Seeking Alpha(Thu, Mar 21)
- 2 Cancer Stocks Ready To Rallyat Seeking Alpha(Thu, Mar 21)
- Investing In The Medical Diagnostic Device Sector In 2013at Seeking Alpha(Thu, Mar 21)
- MELA SCIENCES, INC. /NY Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online(Wed, Mar 20)
- MELA Sciences, Inc. Presents New Data That Reinforces The Importance Of MelaFind® As A Diagnostic Tool At AAD MeetingPR Newswire(Mon, Mar 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 168.46 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.68 |
|---|
| Quarterly EPS Est
(Mar-13)
: | -0.18 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | -0.07 |
|---|
Business Summary
MELA Sciences, Inc., a medical device company, designs, develops, and commercializes a non-invasive point-of-care instrument to aid in the detection of melanoma.
View More